Swiss National Bank Assembly Biosciences, Inc. Transaction History

Swiss National Bank

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 06, 2021	SELL	$3.8 - $4.56 $267,900 - $321,480	-70,500 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$15.08 - $27.04 $34,684 - $62,192	2,300 Added 3.37%	70,500 $1.16 Million
Q2 2020 Aug 05, 2020	BUY	$14.57 - $23.96 $199,609 - $328,252	13,700 Added 25.14%	68,200 $1.59 Million
Q1 2020 May 08, 2020	BUY	$10.27 - $21.23 $9,243 - $19,107	900 Added 1.68%	54,500 $808,000
Q4 2019 Feb 06, 2020	BUY	$8.36 - $23.81 $91,124 - $259,529	10,900 Added 25.53%	53,600 $1.1 Million
Q2 2019 Aug 02, 2019	BUY	$12.9 - $20.8 $41,280 - $66,560	3,200 Added 8.1%	42,700 $576,000
Q1 2019 May 10, 2019	BUY	$17.7 - $24.93 $23,010 - $32,409	1,300 Added 3.4%	39,500 $778,000
Q4 2018 Feb 13, 2019	BUY	$19.05 - $36.45 $59,055 - $112,995	3,100 Added 8.83%	38,200 $864,000
Q3 2018 Nov 08, 2018	BUY	$34.41 - $44.23 $216,782 - $278,649	6,300 Added 21.88%	35,100 $1.3 Million
Q1 2018 May 04, 2018	BUY	$41.7 - $64.16 $20,850 - $32,080	500 Added 1.77%	28,800 $1.42 Million
Q4 2017 Feb 07, 2018	BUY	$28.58 - $49.91 $808,814 - $1.41 Million	28,300	28,300 $1.28 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $723M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.